Close

Form 6-K ASTRAZENECA PLC For: Apr 29

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. SPY
3. SPOT
4. GM
5. AMZN
6. SHW
7. AAPL
8. IBM
9. MINN
10. NVDA


April 29, 2016 1:13 PM EDT
 

FORM 6-K


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of April 2016

Commission File Number:  001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X            Form 40-F  __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  __                 No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):   82-_____________

 
ASTRAZENECA PLC - ANNUAL GENERAL MEETING 2016
 
Results of Annual General Meeting held on 29 April 2016
 
AstraZeneca PLC announced the results of the voting at its Annual General Meeting today.  As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 11 were passed as special resolutions.
 
 
 
RESOLUTION
VOTES FOR
% OF VOTES CAST
VOTES AGAINST
% OF VOTES CAST
VOTES CAST IN TOTAL
TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL
VOTES WITHHELD
1
To receive the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2015
 
924,514,473
99.61
3,665,459
0.39
928,179,932
73.40%
8,998,621
2
To confirm dividends
 
933,191,043
99.69
2,915,972
0.31
936,107,015
74.03%
1,071,537
3
To re-appoint KPMG LLP, London as Auditor
 
929,918,594
99.56
4,151,154
0.44
934,069,748
73.87%
3,108,804
4
To authorise the Directors to agree the remuneration of the Auditor
 
934,984,319
99.89
988,556
0.11
935,972,875
74.02%
1,204,865
5a
To re-elect Leif Johansson as a Director
 
861,678,834
94.69
48,321,545
5.31
910,000,379
71.96%
27,177,942
5b
To re-elect Pascal Soriot as a Director
 
935,167,473
99.93
697,471
0.07
935,864,944
74.01%
1,342,796
5c
To re-elect Marc Dunoyer as a Director
 
931,875,086
99.58
3,920,615
0.42
935,795,701
74.00%
1,380,982
5d
To re-elect Cori Bargmann as a Director
 
935,157,654
99.93
635,873
0.07
935,793,527
74.00%
1,384,110
5e
To re-elect Geneviève Berger as a Director
 
935,199,102
99.93
622,099
0.07
935,821,201
74.00%
1,356,436
5f
To re-elect Bruce Burlington as a Director
 
933,026,505
99.70
2,762,355
0.30
935,788,860
74.00%
1,389,088
5g
To re-elect Ann Cairns as a Director
 
933,220,149
99.72
2,618,183
0.28
935,838,332
74.01%
1,339,989
5h
To re-elect Graham Chipchase as a Director
 
919,686,570
98.97
9,526,012
1.03
929,212,582
73.48%
7,965,366
5i
To re-elect Jean-Philippe Courtois as a Director
 
933,177,891
99.72
2,593,420
0.28
935,771,311
74.00%
1,406,637
5j
To re-elect Rudy Markham as a Director
 
923,984,532
98.74
11,766,347
1.26
935,750,879
74.00%
1,427,442
5k
To re-elect Shriti Vadera as a Director
 
927,479,182
99.11
8,287,726
0.89
935,766,908
74.00%
1,410,552
5l
To re-elect Marcus Wallenberg as a Director
 
870,828,312
95.76
38,511,577
4.24
909,339,889
71.91%
27,837,158
6
To approve the Annual Report on Remuneration for the year ended 31 December 2015
836,396,151
89.61
96,959,428
10.39
933,355,579
73.81%
3,822,290
7
To authorise limited EU political donations
 
908,106,542
97.83
20,185,176
2.17
928,291,718
73.41%
8,886,009
8
To authorise the Directors to allot shares
 
849,809,843
90.97
84,303,774
9.03
934,113,617
73.87%
3,064,122
9
To authorise the Directors to disapply pre-emption rights
 
922,425,478
98.82
11,009,374
1.18
933,434,852
73.82%
3,742,888
10
To authorise the Company to purchase its own shares
 
926,166,577
98.96
9,722,078
1.04
935,888,655
74.01%
1,289,613
11
To reduce the notice period for general meetings
 
829,946,353
88.85
104,116,202
11.15
934,062,555
73.87%
3,115,081
 
 
 
Issued capital
As at 27 April 2016, the number of issued shares of the Company was 1,264,542,488 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM.  In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
 
 
A C N Kemp
Company Secretary
29 April 2016

 
 
 SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
AstraZeneca PLC

 
Date: 29 April 2016
By:  /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary
 

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings